720054Enterprise DynamikaClosedGRD Development of PrototypeInnovate UKMRI is a major tool in clinical routine since it enables early diagnosis and reliable assessment of treatment, especially in arthritis and oncology studies, where timely diagnosis can make a difference between a disability or even death and a recovery to a relatively normal lifestyle. However, the cost of MRI procedures limits its use, which impacts on patient outcomes. To limit costs and to increase use of MRI radiologists need the best tools to aid their diagnostic procedures. Computer Aided Detection (CAD) solutions automate clinical routine, optimise treatment pathways, and enable earlier diagnosis, leading to overall costs savings in healthcare organisations and improvement of patient outcomes. However, CAD originates in academia and rarely finds its way to clinical routine. This project will extend functionality of IA’s proprietary solution Dynamika, widely deployed in rheumatoid arthritis into detection of prostate and breast cancer. We will further to deliver a prototype of an infrastructure for a faster deployment of this first multi-disease comprehensive MRI CAD solution in clinical routine. Centres of excellence (Oxford, Imperial, UCLH) will be used for R&D guidance, development of this innovative solution and its validation. IA will partner with key service providers (Agfa, Accenture) to build up the infrastructure, enabling academics to transfer their research into clinical practice and clinicians to have access to the latest cutting edge scientific findings. The grant will aid the significant technical development required to build and validate this infrastructure. IA has a track record of successful collaborative work with academia and hands on experience in developing innovative CAD tools. The output of the project will be a UK-wide deployment of MRI CAD solutions for better clinical diagnosis in rheumatoid arthritis, breast, and prostate cancer. The grant will facilitate intense R&D and to allow rapid development and growth of the company.